title: [Management of patients with essential thrombocythemia].
authors.affiliation: Servicio de Hematología y Hemoterapia, Hospital Virgen de la Victoria, Málaga, España.
authors.forename: Gemma
authors.initials: G
authors.lastname: Ramirez
authors.forename: Ricarda
authors.initials: R
authors.lastname: García-Sanchez
authors.forename: Sylvia
authors.initials: S
authors.lastname: Plaza
mesh_terms: D000328:Adult; D000368:Aged; D001853:Bone Marrow / Q000473:pathology; D054697:Cytostatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D019468:Disease Management; D005260:Female; D020022:Genetic Predisposition to Disease; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use; D053614:Janus Kinase 2 / Q000235:genetics; D007774:Lactation; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D017354:Point Mutation; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000188:drug therapy; D011799:Quinazolines / Q000627:therapeutic use; D013920:Thrombocythemia, Essential / Q000145:classification / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology; D019851:Thrombophilia / Q000188:drug therapy / Q000209:etiology
chemical_list: D054697:Cytostatic Agents; D016898:Interferon-alpha; D010975:Platelet Aggregation Inhibitors; D011799:Quinazolines; C507924:JAK2 protein, human; D053614:Janus Kinase 2; C021139:anagrelide